TY - JOUR
T1 - High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
AU - Rossi, Lorena
AU - Santoni, Matteo
AU - Crabb, Simon J.
AU - Scarpi, Emanuela
AU - Burattini, Luciano
AU - Chau, Caroline
AU - Bianchi, Emanuela
AU - Savini, Agnese
AU - Burgio, Salvatore L.
AU - Conti, Alessandro
AU - Conteduca, Vincenza
AU - Cascinu, Stefano
AU - De Giorgi, Ugo
PY - 2015
Y1 - 2015
N2 - Background: Increased neutrophil-to-lymphocyte ratio (NLR), an index of systemic inflammation, is associated with poor outcome for various types of cancers. We assessed the role on outcome prediction of NLR at baseline and persistent during first-line chemotherapy in patients with advanced urothelial cancer. Methods: We retrospectively reviewed 292 patients with unresectable or metastatic urothelial cancer treated with first-line chemotherapy between January 2003 and December 2012. The cutoff values of NLR (>3 vs. 12 g/dL), pretherapy NLR (>3 vs. 3 vs. ≤3). Results: Patients with pre- and follow-up NLR of >3 had a median progression-free survival of 3.2 months and a median overall survival of 5.7 months. In multivariate analysis, visceral metastases, pretherapy hemoglobin, and follow-up NLR were significant predictors of progression-free survival [hazard ratio (HR) 1.75, P = 0.0001; HR 1.57, P = 0.0015; HR 2.77, P
AB - Background: Increased neutrophil-to-lymphocyte ratio (NLR), an index of systemic inflammation, is associated with poor outcome for various types of cancers. We assessed the role on outcome prediction of NLR at baseline and persistent during first-line chemotherapy in patients with advanced urothelial cancer. Methods: We retrospectively reviewed 292 patients with unresectable or metastatic urothelial cancer treated with first-line chemotherapy between January 2003 and December 2012. The cutoff values of NLR (>3 vs. 12 g/dL), pretherapy NLR (>3 vs. 3 vs. ≤3). Results: Patients with pre- and follow-up NLR of >3 had a median progression-free survival of 3.2 months and a median overall survival of 5.7 months. In multivariate analysis, visceral metastases, pretherapy hemoglobin, and follow-up NLR were significant predictors of progression-free survival [hazard ratio (HR) 1.75, P = 0.0001; HR 1.57, P = 0.0015; HR 2.77, P
UR - http://www.scopus.com/inward/record.url?scp=84925498897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925498897&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-4097-4
DO - 10.1245/s10434-014-4097-4
M3 - Article
C2 - 25234022
AN - SCOPUS:84925498897
VL - 22
SP - 1377
EP - 1384
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 4
ER -